Reproductive Health
Ferring is a world leader in Assisted Reproductive Technology (ART) for fertility treatment. Ferring’s on-going research efforts in this area strive to meet the growing needs of patients as increasing numbers of couples seek help to conceive. Ferring also offers a range of peptide-based medicines in obstetric care - labour induction, and to prevent preterm birth and postpartum haemorrhage.
Urology
Ferring is committed to the development of medicines to treat urological disorders such as diabetes insipidus, enuresis and nocturia.
Prostate cancer is another disease area where Ferring also actively engages in. We are conducting clinical studies to further demonstrate the benefits of therapy using (GnRH) receptor antagonist monthly depot in the management of advanced prostate cancer.
Gastroenterology
Ferring has a strong heritage of educational support, sponsorship and clinical research within Inflammatory Bowel Disease (IBD). A series of developmental initiatives are underway to bring new products in this indication to market. Recently, Ferring has also launched colonic-release oral corticosteroid.
The Ferring gastroenterology portfolio also includes bowel preparation (to prepare patients for colonoscopy) and the pharmacological treatment for complications resulting from end-stage liver cirrhosis.
Endocrinology
Ferring has peptide-based medicines targeting pituitary malfunctioning which causes growth failure in children.
Orthopaedics
Ferring has recently started the development in the orthopaedic area to help knee osteoarthritis sufferers to reduce pain.
